Indications
Riulvy is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
Composition
- Active substance
- tegomil fumarate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Riulvy
- Active substance
- tegomil fumarate
- ATC code
- L04AX10
- Therapeutic area
- Multiple Sclerosis, Relapsing-Remitting
- Marketing authorisation holder
- Neuraxpharm Pharmaceuticals S.L.
- Status
- Authorised
- EU authorisation